SCIENCE@home

Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling

P. Gao,Chunzhang Yang,Cody L. Nesvick,M. J. Feldman,Saman Sizdahkhani,Huailei Liu,Huiying Chu,Fengxu Yang,Ling Tang,Jing Tian,Shiguang Zhao,Guohui Li,John D Heiss,Yang Liu,Z. Zhuang,Guowang Xu

Published 2016 in OncoTarget

ABSTRACT

Metabolomics has shown significant potential in identifying small molecules specific to tumor phenotypes. In this study we analyzed resected tissue metabolites using capillary electrophoresis-mass spectrometry and found that tissue hypotaurine levels strongly and positively correlated with glioma grade. In vitro studies were conducted to show that hypotaurine activates hypoxia signaling through the competitive inhibition of prolyl hydroxylase domain-2. This leads to the activation of hypoxia signaling as well as to the enhancement of glioma cell proliferation and invasion. In contrast, taurine, the oxidation metabolite of hypotaurine, decreased intracellular hypotaurine and resulted in glioma cell growth arrest. Lastly, a glioblastoma xenograft mice model was supplemented with taurine feed and exhibited impaired tumor growth. Taken together, these findings suggest that hypotaurine is an aberrantly produced oncometabolite, mediating tumor molecular pathophysiology and progression. The hypotaurine metabolic pathway may provide a potentially new target for glioblastoma diagnosis and therapy.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-62 of 62 references · Page 1 of 1

CITED BY

Showing 1-45 of 45 citing papers · Page 1 of 1